Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Mutational landscape of adult xanthogranuloma

Blood (2025) 146 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2025-7339

Published: 2025

Journal Articles

Intratumoral B cell diversity in follicular lymphoma revealed by single-cell paired transcriptome and BCR sequencing

Miranda Siminski, Janek Walker, Joseph Novak, Abigail Dropik, Zilin Xianyu, Zhi-Zhang Yang, Matthew Maurer, Thomas Habermann, Rebecca King, Thomas Witzig, Stephen Ansell, James Cerhan, Patrizia Mondello, Anne Novak

Blood (2025) 146 (Supplement 1): 5342.

https://doi.org/10.1182/blood-2025-5342

Published: 2025

Journal Articles

Evolving insights and changes in survival of erdheim-chester disease over time

Blood (2025) 146 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2025-2990

Published: 2025

Journal Articles

NOTCH pathway activation is mediated by DTX1 loss of function mutations in DLBCL

Blood (2025) 146 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2025-1771

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping

Blood (2025) 146 (Supplement 1): 117.

https://doi.org/10.1182/blood-2025-117

Published: 2025

Journal Articles

Anatomical localization-based analysis of de novo secondary cns lymphoma

Izel Okcu, Zhuo Li, Launia White, Yucai Wang, Patrick Johnston, Allison Rosenthal, Arushi Khurana, Urshila Durani, Jonas Paludo, Rebecca King, Thomas Witzig, Thomas Habermann, Grzegorz Nowakowski, Han Tun

Blood (2025) 146 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2025-3675

Published: 2025

Journal Articles

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Julia Wang, Steven Hwang, Urshila Durani, Gita Thanarajasingam, Arushi Khurana, Jonas Paludo, Yucai Wang, Grzegorz Nowakowski, Thomas Habermann, Thomas Witzig, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2025-5399

Published: 2025

Journal Articles

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Blood (2025) 146 (Supplement 1): 5439.

https://doi.org/10.1182/blood-2025-5439

Published: 2025

Journal Articles

Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)

Blood (2025) 146 (Supplement 1): 5301.

https://doi.org/10.1182/blood-2025-5301

Published: 2025

Journal Articles

Genetic evolution of Waldenström macroglobulinemia across disease stages

Blood (2025) 146 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2025-3540

Published: 2025

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML)

Abhishek Mangaonkar, Jenna Fernandez, Ashya Burgess, Kristen McCullough, Christy Finke, Terra Lasho, Michelle Amundson, Antoine Saliba, Aasiya Matin, Aref Al-Kali, Hassan Alkhateeb, Mithun Shah, Betsy Knopf, Thomas Witzig, Mrinal Patnaik

Blood (2025) 146 (Supplement 1): 2079.

https://doi.org/10.1182/blood-2025-2079

Published: 2025

Journal Articles

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Blood (2025) 146 (Supplement 1): 6760.

https://doi.org/10.1182/blood-2025-6760

Published: 2025

Journal Articles

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Blood (2025) 146 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2025-1007

Published: 2025

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Muhammad A. Mir, Matthew J. Maurer, Steven C. Ziesmer, Susan L. Slager, Thomas Habermann, William R. Macon, Brian K. Link, Sergei Syrbu, Thomas Witzig, Jonathan W. Friedberg, Oliver Press, Michael LeBlanc, James R. Cerhan, Anne Novak, Stephen M. Ansell

Blood (2015) 125 (6): 992–998.

https://doi.org/10.1182/blood-2014-06-583369

Published: 2015

Includes: Supplemental data

Journal Articles

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Julie M. Vose, M.D., Thomas Habermann, Myron S Czuczman, Pier Luigi Zinzani, Craig B. Reeder, MD, Joseph Tuscano, MD, Izidore S Lossos, MD, Dennis Pietronigro, Annette Ervin-Haynes, Thomas Witzig

Blood (2009) 114 (22): 2699.

https://doi.org/10.1182/blood.V114.22.2699.2699

Published: 2009

Journal Articles

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Anne Novak, Takashi Akasaka, Michelle Manske, Mamta Gupta, Thomas Witzig, Martin JS Dyer, Ahmet Dogan, Ellen Remstein, Stephen Ansell

Blood (2008) 112 (11): 2251.

https://doi.org/10.1182/blood.V112.11.2251.2251

Published: 2008

Journal Articles

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Blood (2008) 112 (11): 91.

https://doi.org/10.1182/blood.V112.11.91.91

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Mutational landscape of adult xanthogranuloma

Intratumoral B cell diversity in follicular lymphoma revealed by single-cell paired transcriptome and BCR sequencing

Evolving insights and changes in survival of erdheim-chester disease over time

NOTCH pathway activation is mediated by DTX1 loss of function mutations in DLBCL

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Lymphovision: A lymphoma-specialized foundation model for histology-based lymphoma classification and subtyping

Anatomical localization-based analysis of de novo secondary cns lymphoma

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Shorter diagnosis to treatment interval is associated with poor prognosis in patients with peripheral T-cell lymphoma: Analysis from the LEO and MER cohorts

Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)

Genetic evolution of Waldenström macroglobulinemia across disease stages

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML)

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Outcomes in the 2nd decade following follicular lymphoma (FL) diagnosis: Long-term follow-up from the university of Iowa/Mayo Clinic SPORE molecular epidemiology resource (MER)

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma

Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant.

Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only